CD8A and leishmaniasis: An ideal vaccine against Leishmaniasis must have several attributes: (1) safety, (2) accessibility for populations at risk, (3) induce long-lasting CD4 and CD8 specific T cell response, (4) be effective against Leishmania species responsible for visceral and tegumentary forms, (5) stability at room temperature to be used in the field, and (6) have prophylactic and therapeutic potential (74).